Home > Insider Trading > Filing (0001225208-25-000208)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885725	Boston Scientific Corp	BSX	Surgical & Medical Instruments & Apparatus (3841)	042695240

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1629277	Bradley John Sorenson	300 Boston Scientific Way Marlborough MA 01752-1234	Evp, Global Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-01-01	4,469	$0.00	41,565	No	4	M	Direct
Common Stock	Disposition	2025-01-01	2,127	$89.32	39,438	No	4	F	Direct
Common Stock	Disposition	2025-01-02	4,119	$90.02	35,319	No	4	S	Direct
Common Stock	Disposition	2025-01-03	2,342	$89.86	32,977	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Share Units	Disposition	2025-01-01	4,469	$0.00	4,469	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2024-12-31	2024-12-31	No	4	M	Direct

Footnotes

On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.